2 testing labs in Serbia get boost from China
Chinese genomics company BGI Group signed an agreement with the Serbian government on Wednesday to help the European country build two coronavirus testing laboratories, as the pandemic continues to rage across the continent.
The two labs, one located in Belgrade, the Serbian capital, and the other in the southern city of Nis, will be capable of testing a combined 3,000 samples per day once they begin to operate, significantly boosting the country's testing capabilities.
The Belgrade lab will be built at the country's national medical center, which is currently being renovated.
"Thank you for what you have done for the Serbian people at this difficult time," Serbian Prime Minister Ana Brnabic told BGI. "We have received support and help from China in medical supplies, experts, technology and experience from our first day of battling the coronavirus. Without Chinese help, we would not be able to win the battle."
Chinese Ambassador to Serbia Chen Bo said the embassy will continue to provide help so that the two labs can begin operating as soon as possible.
Wang Jian, BGI's founder and chairman, said testing is crucial for early detection and control of the coronavirus. It can effectively prevent delays of medical treatment and reduce public panic.
Looking for chemical products? Let suppliers reach out to you!
Oversupply of methanol will not change
2026-07-01
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
The project of fine chemicals with 4000 t/a Tebuconazole and Diflufenican is to be built
-
Pharmaconex 2022
-
CPHI Korea 2022
-
Shandong Pharmaceutical Companies Grab Over $1 Billion of Antithrombotic Drugs for The First Imitation, Original Research Drugs Soared 5527%
-
ECHEMI International Trade Business School Bangladesh Pharmaceutical Summary
-
Industrialization Progress of genetically modified pharmaceutical products
-
2022 Top 50 Global Pharmaceutical Companies Released! Pfizer Returns to NO.1, Kexing Counterattack First on the List
-
Pharmaceutical and Health Industry Special Study - The Arrival of New Opportunities
-
Accelerate Technological Breakthroughs in Product Innovation and Promote the Industrialization and Application of Innovative Drugs
-
The Rare Disease Market Continues to Heat Up. How Will The Global Top 10 Pharmaceutical Companies by Revenue in 2021 be Deployed?
Recommend Reading
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
West Asia’s Conflict Is Testing the Hidden Fragility of Pharma Trade
-
South Africa Wants Lenacapavir at Home, Not Just Imported
-
China’s Approval of Pfizer’s GLP-1 Drug Signals a Sharper Obesity Race
-
Methanol Market Prices Fluctuate Narrowly
-
Supply and Demand Game: Flexible Trends in the Chinese Melamine Market
-
Ammonium Sulfate Market Trend in October Shows a Strong Increase in China
-
Soda Ash Market Trends Remain Stable
-
Weak Supply and Demand Continues to Affect the Melamine Market